Abzena, a global partnership research organization providing discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a $10 million investment of growth capital from Biospring Partners, a New York based investment firm. 

The new capital will allow Abzena to further accelerate its growth plans. Abzena drove 80% revenue growth and tripled GMP manufacturing capacity in 1H20.

“The investment by Biospring Partners is further validation that the Abzena integrated model is the future of biologics drug development and manufacturing,” said Jonathan Goldman MD, CEO of Abzena. “Michelle Dipp and Jennifer Lum founded Biospring based upon their deep expertise in life sciences and technology industries. Abzena will benefit from Biospring’s access to a broad network of potential customers and their expertise in building and operating growth stage companies. Access to new customer partners and operating expertise is essential for the continuing growth of the company.”